CARGO Therapeutics has said it plans to offer around 18.8 million shares in the latest bid by a biotech to list on the Nasdaq, amid a desultory year for initial public off
CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k
A question which has long baffled scientists, frustrated clinicians, and devastated patients is why the immune system so effectively defends against infections, but so poorly deals with can
Last week, I had the privilege of heading into town in Boston to attend three days of the CAR-TCR conference, a major annual gathering of researchers and industry stakeholders concerned wit
Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o